Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the first launch of BRIUMVI (ublituximab) in Europe for the treatment of adult patients with relapsing multiple...
Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis...
Octave Bioscience, a precision care company advancing treatments for multiple sclerosis (MS), has announced the publication of the successful clinical validation of its multiple sclerosis disease activity (MSDA) test in the peer-reviewed journal Clinical...
Polpharma Biologics, a biotech company developing and manufacturing biosimilars, has announced that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko.
Sandoz said the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for a natalizumab biosimilar, developed by Polpharma Biologics.
Special Edition: Reviewing the advanced therapy pipeline
Atara Biotherapeutics is working on harnessing Epstein-Barr Virus (EBV) T-cells to help develop a new therapy for multiple sclerosis: saying the first-of-its-kind T-cell immunotherapy could not only slow decline but also help patients regain function...
Scotland will soon have access to the Novartis drug, Kesimpta, (ofatumumab), the first self-administered, targeted B-cell therapy for patients with relapsing remitting multiple sclerosis (RRMS).